H3 Biomedicine
Pharmaceuticals, 300 Technology Square, Cambridge, Massachusetts, 02139, United States, 51-200 Employees
Phone Number: 61********
Who is H3 BIOMEDICINE
H3 Biomedicine is a privately held biopharmaceutical company focused on the discovery and early development of novel, targeted anti-cancer compounds for the unmet needs of genetically def...
Read More
-
Headquarters: 300 Technology Square, Cambridge, Massachusetts, 02139, United States
-
Date Founded: 2011
-
Employees: 51-200
-
Revenue: $25 Million to $50 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from H3 BIOMEDICINE
H3 Biomedicine Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding H3 Biomedicine
Answer: H3 Biomedicine's headquarters are located at 300 Technology Square, Cambridge, Massachusetts, 02139, United States
Answer: H3 Biomedicine's phone number is 61********
Answer: H3 Biomedicine's official website is https://h3biomedicine.com
Answer: H3 Biomedicine's revenue is $25 Million to $50 Million
Answer: H3 Biomedicine's SIC: 2834
Answer: H3 Biomedicine's NAICS: 325412
Answer: H3 Biomedicine has 51-200 employees
Answer: H3 Biomedicine is in Pharmaceuticals
Answer: H3 Biomedicine contact info: Phone number: 61******** Website: https://h3biomedicine.com
Answer: H3 Biomedicine is a privately held biopharmaceutical company focused on the discovery and early development of novel, targeted anti-cancer compounds for the unmet needs of genetically defined patient populations. H3 has leveraged its integrated expertise in genomics, tumor biology, bioinformatics and innovative synthetic organic chemistry to create an integrated drug development ecosystem to deliver patient-based, genomics-driven, small molecule drugs. In less than three years, H3 has developed four discovery platforms, which have produced two drug candidates for which the company expects to file investigational new drug (IND) applications in late 2015. Founded by a $200 million dollar investment from Eisai Inc., and given operational and strategic independence, H3 has delivered on Eisai’s confidence with multiple platforms generating multiple lead programs. Having reached this inflection point, H3 is considering additional collaborators to fully realize the potential of its growing pipeline of lead programs and drug candidates. H3 Biomedicine operates in the spirit of the collaboration and camaraderie encouraged by our corporate culture. Each team member has a unique role to play in the quest to develop new cancer drugs. H3 Biomedicine employees are dedicated and passionate individuals who recognize that our potential as a team is much greater than if any one of us was working alone.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month